Editorial: New Insights Into Understanding and Managing NAFLD

Front Med (Lausanne). 2021 Nov 12:8:777740. doi: 10.3389/fmed.2021.777740. eCollection 2021.

¹ Laboratory of Hepatic and Cardiovascular Diseases, Biochemistry and Molecular Biology Department, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.
² Instituto de Fisiología Experimental (IFISE-CONICET), Rosario, Argentina.
³ Valbiotis, Riom, France.
⁴ Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Research Unit, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria-Hospital Universitario de la Princesa, Madrid, Spain.
⁵ Metabolic Syndrome and Vascular Risk Research Laboratory, Research Unit, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria-Hospital Universitario de la Princesa, Madrid, Spain.
⁶ Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

No abstract available

Keywords: NAFLD (non-alcoholic fatty liver disease); biomarkers; liver pathophysiology; steatohepatitis; therapeutical approaches.

Publication types